KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

Our pipeline, where you -- we'll probably talk about olanzapine, TL1A, ICS/SABA, IL-15, these will all bring growth in ... even with the oral molecule around the metabolic profile. And I imagine ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Repurposing of a drug designed for pain relief can quickly and reversibly slow biochemical and metabolic activities in cells and organs and could facilitate organ transplantation and prevent tissue ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...

DeepCure to Present In Vivo Efficacy and Safety Data of BRD4 (BD2) Inhibitor DC-9476 for Macrophage Activation Syndrome at EMBO Conference ...

Osteoarthritis (OA) is the most common arthritis worldwide, causing pain, disability, and loss of function due to chronic joint ...